G1 Therapeutics to Release Third Quarter 2022 Financial Results and Provide Business Update on November 2, 2022GlobeNewsWire • 10/19/22
Is G1 Therapeutics (GTHX) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 10/12/22
G1 Therapeutics Completes Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Triple Negative Breast Cancer (TNBC)GlobeNewsWire • 10/10/22
MDA Breakout Stocks Week 40 - October 2022: Short-Term Picks To Give You An EdgeSeeking Alpha • 10/03/22
G1 Therapeutics to Participate Virtually in the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 09/07/22
G1 Therapeutics (GTHX)'s Technical Outlook is Bright After Key Golden CrossZacks Investment Research • 08/26/22
Can G1 Therapeutics (GTHX) Climb 150% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 08/08/22
G1 Therapeutics, Inc. (GTHX) CEO Jack Bailey on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/03/22
G1 Therapeutics Provides Second Quarter 2022 Financial Results and Operational HighlightsGlobeNewsWire • 08/03/22
G1 Therapeutics to Participate Virtually in the 2022 BTIG Biotechnology Conference and the 2022 Wedbush Pacgrow Healthcare ConferenceGlobeNewsWire • 08/01/22
Analysts Estimate G1 Therapeutics (GTHX) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 07/27/22
G1 Therapeutics Announces Addition of Norman E. Sharpless to Board of DirectorsGlobeNewsWire • 07/25/22
G1 Therapeutics to Release Second Quarter 2022 Financial Results and Provide Business Update on August 3, 2022GlobeNewsWire • 07/20/22
COSELA® (Trilaciclib Hydrochloride for Injection) Now Approved in China to Decrease the Incidence of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)GlobeNewsWire • 07/13/22
G1 Therapeutics Announces Completion of Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Colorectal CancerGlobeNewsWire • 06/13/22
Data Presented at ASCO Demonstrate Trilaciclib Helps Protect Against Severe Neutropenia, Severe Anemia, and Severe Thrombocytopenia When Given to Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Patients Prior to ChemotherapyGlobeNewsWire • 06/02/22
G1 Therapeutics Named 2022 Life Sciences Public Company of the Year by Triangle Business JournalGlobeNewsWire • 05/20/22
G1 Therapeutics to Participate in the H.C. Wainwright & Co. Global Investment ConferenceGlobeNewsWire • 05/18/22
G1 Therapeutics Provides First Quarter 2022 Financial Results and Operational HighlightsGlobeNewsWire • 05/04/22